cs0159

Primary Sclerosing Cholangitis

Cascade Pharmaceuticals, IncPhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

21 Active assets in the Primary Sclerosing Cholangitis cohort.

Asset / Sponsor	Phase	Rating
Vancomycin Tampere University Hospital	Phase 4	BB
URSODEOXYCHOLIC ACID Assistance Publique - Hôpitaux de Paris	Phase 3	BB
Aldafermin NGM Biopharmaceuticals, Inc	Phase 2/3	B
Elafibranor Ipsen	Phase 3	B
htd1801 HighTide Biopharma Pty Ltd	Phase 2	B

View all 50 →

Same molecule, other indications

cs0159 is also rated in:

primary biliary cholangitisDormant

BB

Indicative ·

68 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

57 / 100

type 2 diabetes mellitusDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.